Table 3 List of some selected ongoing trials of adoptive cell therapy in different subtypes of breast cancer
From: Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
S. no | Phases | Breast cancer subtypes | Precondition | Immuno-therapeutic agents | Estimated participants | Co-adjuvants | Recruitment status | Identifiers |
|---|---|---|---|---|---|---|---|---|
Tumor-infiltrating lymphocyte (TIL) therapy | ||||||||
 1 | II | Metastatic TNBC | Yes | TIL LN-145 | 6 | - | Active, not recruiting | NCT04111510 |
 2 | II | Metastatic cancers including BC (mixed) | Yes | Young TIL | 332 | Anti-PD1 | Recruiting | NCT01174121 |
T-cell receptor (TCR) therapy | ||||||||
 3 | II | BC (mixed) | Yes | Sleeping Beauty Transposed PBL |  | - | Recruiting | NCT04102436 |
 4 | II | Metastatic cancers including BC (mixed) | Yes | Autologous TCR-Transduced PBL | 270 | Anti-PD1 | Recruiting | NCT03412877 |
CAR-T cell therapy | ||||||||
 5 | I | HER2 + solid tumors including BC | Yes | CCT303-406 CAR-modified autologous T cells (CCT303-406) | 15 | - | Recruiting | NCT04511871 |
 6 | I | Metastatic BC (mixed) | No | huMNC2-CAR44 T cells and huMNC2-CAR44 T cells @ RP2D | 69 | - | Recruiting | NCT04020575 |
 7 | I | Brain or Leptomeningeal metastases from HER2 + cancer including BC | No | HER2-CAR T cells | 39 | - | Recruiting | NCT03696030 |
 8 | I | HER2 + cancer including BC | No | HER2-CAR T cells | 45 | CAdVEC oncolytic virus | Recruiting | NCT03740256 |
 9 | I | Refractory neuroblastoma and other GD2 + cancers including BC | Yes | C7R-GD2.CAR-T cells | 94 | - | Recruiting | NCT03635632 |
 10 | I | Advanced solid tumors including recurrant BC | No | EpCAM CAR-T cells | 30 | - | Recruiting | NCT02915445 |
 11 | I | BC (mixed), metastatic HER2-negative BC | Yes | Mesothelin-targeted T cells | 186 | - | Active, not recruiting | NCT02792114 |
 12 | I/II | BC (mixed) | No | Multi-4SCAR-T cells | 100 | - | Recruiting | NCT04430595 |
 13 | I/II | Relapsed/refractory CEA + cancer including BC | No | CEA CAR-T cells | 40 | - | Recruiting | NCT04348643 |
 14 | I/II | CD44v6 + cancer including BC | No | CD44v6-specific CAR-T cells | 100 | - | Recruiting | NCT04427449 |
 15 | I/II | CD70 expressing cancers including BC | Yes | Anti-hCD70 CAR-transduced PBL | 124 | - | Recruiting | NCT02830724 |
 16 | I/II | Different types of cancer including BC (mixed) | Yes | iCasp9M28z T cell infusions | 113 | Anti-PD1 | Active, not recruiting | NCT02414269 |
Dendritic cell (DC) therapy | ||||||||
 17 | I | HER2 + BC | No | HER-2 pulsed DC vaccine | 15 | - | Active, not recruiting | NCT02063724 |
 18 | I | HER2 + BC | No | HER-2 pulsed DC vaccine | 7 | - | Active, not recruiting | NCT02061423 |
 19 | I | HER2 + BC (mixed) | No | DC vaccine (DC1) | 31 | - | Active, not recruiting | NCT03387553 |
 20 | II | HER2 + BC (mixed) | No | DC vaccine (DC1) | 119 | - | Active, not recruiting | NCT03384914 |
 21 | II | BC (mixed) | No | DC-CIK immunotherapy | 400 | CIK | Active, not recruiting | NCT02491697 |
 22 | II | Asymptomatic brain metastasis from TNBC or HER2 + BC | No | Anti-HER2/HER3 DC vaccine | 23 | Anti-PD1, IFNa2b | Recruiting | NCT04348747 |
Natural killer (NK) cell therapy | ||||||||
 23 | I | Advanced or metastatic HER2-expressing solid tumors including BC | Yes | ACE1702 | 36 | - | Recruiting | NCT04319757 |